Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pavblu Prefilled Syringe Usability Study
NCT05704725Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), diabetic retinopathy (DR), sponsored by Amgen. Started Jan 2023; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)retinal vein occlusion (RVO)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05704725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704725.